28 completed, 6 recruiting, 4 active not recruiting, 4 unknown. 18 Phase 2, 15 Phase 1, 7 Phase 3, 4 Not applicable, 1 Early Phase 1.
Follow Cervical Squamous Cell Carcinoma: new trials by email Literature Review of Cervical Squamous Cell Carcinoma trials Research Report on Cervical Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Feasibility Study of Blood Biomarker Identification in Cervical Cancer Blood Sample Collection, cfDNA and Extracellular Vesicle Biomarker Analysis, Patient-Reported Outcome and Quality-of-Life Assessment - Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma | Recruiting | Queensland Centre for Gynaecological Cancer | 100 | 2026-09-15 | 2026-09-02 | |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas EVOLVE104 - Bladder Cancer, Squamous Cell Carcinoma of the Lung | Phase 1 | Recruiting | EvolveImmune United, Inc | 160 | 2025-11-13 | 2026-09-15 |
| Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma (ESCC), Cervical Squamous Cell Carcinoma | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 800 | 2025-09-12 | 2026-09-18 | |
| A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors ALE.P03 - Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Alentis Therapeutics AG | 180 | 2025-08-26 | 2026-07-02 |
| External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer Bevacizumab, Biospecimen Collection, Brachytherapy - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 35 | 2025-07-29 | 2026-08-12 |
| A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors ALE.P02 - Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Alentis Therapeutics AG | 170 | 2024-12-16 | 2026-06-29 |
| A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers HMBD-001, Docetaxel, Cetuximab - Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Hummingbird Bioscience | 398 | 2024-02-05 | 2026-05-27 |
| Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications BBI-355, Erlotinib, Futibatinib - Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma | Phase 1 | Terminated | Boundless Bio, Inc. | 85 | 2023-03-24 | 2026-08-19 |
| Primary Cervical Cancer Screening by Self-sampling HPV Test Human Papillomavirus Infection, Cervical Cancer | Active not recruiting | Peking University People's Hospital | 17875 | 2022-11-19 | 2023-12-21 | |
| Clinical Evaluation of Detection of High Risk HPV in Urine Human Papillomavirus Infection, Cervical Cancer | Unknown | Peking University People's Hospital | 1000 | 2021-09-15 | 2022-01-27 | |
| Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin - Cervical Squamous Cell Carcinoma | Phase 1 | Unknown | Ruijin Hospital | 15 | 2021-09-01 | 2021-08-24 |
| Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma Nimotuzumab, EBRT combined with brachytherapy - Cervical Squamous Cell Carcinoma | Not yet recruiting | Peking University Third Hospital | 125 | 2021-07-01 | 2021-07-26 | |
| A Prospective Study of the Early Treatment of Recombinant Human Thrombopoietin for Chemoradiation Induced Thrombocytopenia in Cervical Squamous Cell Carcinoma Patient rhTPO - Cervical Squamous Cell Carcinoma | Not applicable | Completed | Mei Feng | 75 | 2021-02-01 | 2026-06-16 |
| Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma Nimotuzumab, Cisplatin, External-beam radiation - Cervical Squamous Cell Carcinoma | Not applicable | Unknown | Peking University Third Hospital | 286 | 2020-12-01 | 2020-12-22 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. Obinutuzumab, naptumomab estafenatox and durvalumab, Naptumomab estafenatox and durvalumab - ER+ Breast Cancer, Ovarian Cancer | Phase 1 | Active not recruiting | NeoTX Therapeutics Ltd. | 120 | 2019-10-10 | 2025-11-28 |
| Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer Atezolizumab, Brachytherapy, Cisplatin - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2019-01-07 | 2025-11-12 |
| Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma Nimotuzumab, Paclitaxel, Cisplatin - Cervical Squamous Cell Carcinoma, Persistent | Phase 3 | Completed | Biotech Pharmaceutical Co., Ltd. | 118 | 2017-07-06 | 2025-01-17 |
| Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers Brachytherapy, Cisplatin, External Beam Radiation Therapy - Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 450 | 2016-05-10 | 2026-10-22 |
| Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Laboratory Biomarker Analysis, Nanoparticle Albumin-Bound Rapamycin, Quality-of-Life Assessment - Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma | Early Phase 1 | Completed | Mayo Clinic | 2 | 2016-01-01 | 2019-06-06 |
| Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer Nerve-Sparing Radical Hysterectomy - Cervical Squamous Cell Carcinoma, Cervical Adenocarcinoma | Phase 2 | Completed | Shanghai Gynecologic Oncology Group | 62 | 2015-09-01 | 2016-10-14 |
Showing 20 of 46. Sign in to see all of them.
Uterine Cervical Neoplasms (30) · Esophageal Squamous Cell Carcinoma (5) · Squamous Cell Carcinoma of Head and Neck (5) · Carcinoma, Squamous Cell (3) · Endometrial Neoplasms (3) · Papillomavirus Infections (3) · Urinary Bladder Neoplasms (3) · Adenocarcinoma (2) · Adenocarcinoma in Situ (2) · Anus Neoplasms (2) · Atypical Squamous Cells of the Cervix (2) · Carcinoma, Adenosquamous (2) · Carcinoma, Renal Cell (2) · Neoplasms (2) · Ovarian Neoplasms (2)
Neoplasms by Site (37) · Neoplasms (36) · Female Urogenital Diseases (32) · Female Urogenital Diseases and Pregnancy Complications (32) · Urogenital Diseases (32) · Genital Diseases (31) · Urogenital Neoplasms (31) · Genital Diseases, Female (30) · Genital Neoplasms, Female (30) · Uterine Diseases (30) · Uterine Cervical Diseases (29) · Uterine Neoplasms (29) · Carcinoma (12) · Neoplasms by Histologic Type (12) · Neoplasms, Glandular and Epithelial (12)
Cisplatin (12) · Brachytherapy (8) · Paclitaxel (6) · Taxes (6) · 1,2-diaminocyclohexaneplatinum II citrate (5) · Platinum (5) · Bevacizumab (4) · Radiation (4) · Cetuximab (3) · Disulfides (3) · Immunoglobulin G (3) · Radiotherapy (3) · Topotecan (3) · nimotuzumab (3) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (2)
National Cancer Institute (NCI) (13) · Gynecologic Oncology Group (9) · Alentis Therapeutics AG (2) · Mayo Clinic (2) · Peking University People's Hospital (2) · Peking University Third Hospital (2) · Advaxis, Inc. (1) · Biotech Pharmaceutical Co., Ltd. (1) · Boundless Bio, Inc. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · EvolveImmune United, Inc (1) · GOG Foundation (1) · Hummingbird Bioscience (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1)
United States (32) · China (9) · Canada (7) · South Korea (4) · Spain (4) · Singapore (3) · Taiwan (3) · Australia (2) · France (2) · Hong Kong (2) · Italy (2) · Belgium (1) · India (1) · Israel (1) · Japan (1)
Bradley Monk (2) · Peter Rose (2) · Alessandro Santin (1) · Allan L Covens (1) · Amit M Oza (1) · Anna Tinker (1) · Charles A Leath (1) · Charles Kunos (1) · Charles Levenback (1) · D. McMeekin (1) · Dana M Chase, MD (1) · David Alberts (1) · Dennis Kuo (1)
PMID 19931137, PMID 24395863, PMID 24552320, PMID 25638326, PMID 28756902, PMID 29163840, PMID 29868473, PMID 31681600, PMID 31871115, PMID 32847980, PMID 36898292, PMID 37650664
U10CA027469 (15), U10CA180868 (6), 2025 (1), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), N01CM37008 (1), N01CM62204 (1), P30CA013330 (1), P30CA015083 (1), U10CA101165 (1), U10CA180821 (1), UG1CA189867 (1), UM1CA186705 (1)